Divis Lab Q4 PAT rises 29% YoY to Rs 502 cr

Image
Capital Market
Last Updated : May 31 2021 | 9:50 AM IST

On a consolidated basis, Divi's Laboratories posted a 29.3% rise in net profit to Rs 502.02 crore in Q4 FY21 compared with Rs 388.23 crore in Q4 FY20.

Net sales increased 28.7% year on year to Rs 1,788.19 crore in Q4 FY21 as against Rs 1,389.71 crore in Q4 FY20. Profit before tax stood at Rs 669.49 crore in Q4 FY21, up 42.2% over Rs 470.96 in Q4 FY20.

The drug major reported a forex gain of Rs 3 crore in Q4 FY21 compared with forex gain of Rs 57 crore in Q4 FY20.

For the financial year ended 2020-21, Divi's Laboratories reported a consolidated total income of Rs 7,032 crore as against Rs 5,584 crore during the previous year, reflecting a growth of 26%. Profit after tax for the year amounted to Rs 1,984 crore as against Rs 1,377 crore reported last year, reflecting a growth of 44%.

During the financial year 2020-21, the company capitalised assets of Rs 1,183.51 crore, and an amount of Rs 710.62 crore is carried forward as capital work-in-progress at the end of the year. The new brownfield DC and DCV SEZ units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the year. Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year, the company took up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year

The board has proposed a dividend of Rs 20 per share for the financial year ended 2020-21.

Divis Laboratories is the leading manufacturer of APIs (Active pharmaceuticals ingredients), intermediates and registered starting materials offering high quality products with the highest level of compliance and integrity to over 95 countries.

Shares of Divi's Laboratories were up 0.52% at Rs 4,137.95 on BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 31 2021 | 9:23 AM IST

Next Story